Independent intelligence for the laboratory world

Teknova and Pluristyx Prepare FDA Drug Master File for PluriFreeze

Teknova and Pluristyx are preparing an FDA Drug Master File for the PluriFreeze cryopreservation system.

Press release summary

Alpha Teknova and Pluristyx said Oct. 2 that Pluristyx is completing a Type II Drug Master File for the PluriFreeze cryopreservation system for submission to the U.S. Food and Drug Administration. The filing is intended to support advanced-therapy developers that use the system during preclinical work and later incorporate it into clinical development or manufacturing.

Developers may request a letter of authorization allowing the FDA to reference confidential chemistry, manufacturing and controls information in an Investigational New Drug application or Biologics License Application. PluriFreeze combines a protective cellular wash with a low-viscosity freezing medium containing 10% dimethyl sulfoxide. The companies say the synthetic, animal-origin-free system is available for research and good manufacturing practice applications. Teknova manufactures and distributes the products in the United States and Canada.

Why it matters for laboratories

A Drug Master File can reduce repetitive documentation work when cell-therapy developers move a cryopreservation process from research into regulated manufacturing. It does not represent FDA approval of the product or a therapy. Process-development and quality laboratories should still evaluate cell recovery, viability, comparability, sterility, storage stability and material compatibility for their own cell types and workflows before adoption.

Original source: Teknova announcement.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *